{
    "nct_id": "NCT00751907",
    "title": "Impact of Atorvastatin on Cerebral Perfusion and Endothelial Function",
    "status": "COMPLETED",
    "last_update_time": "2019-09-04",
    "description_brief": "The purpose of this study is to evaluate the hypothesis that in middle-aged, asymptomatic, adult children of persons with Alzheimer's disease (AD), atorvastatin therapy will beneficially affect mechanisms thought to contribute to AD risk by improving blood flow in the brain, improving cerebral perfusion, increasing brain activity patterns, and improving blood vessel function.",
    "description_detailed": "Treatment with cholesterol-lowering medications, specifically statins, is associated with up to a 73% reduction in the prevalence of AD, suggesting a potentially promising role for statins in the prevention of AD. In order to better understand the mechanisms through which statins may possibly modify blood AD risk, this study evaluated whether administration of atorvastatin favorably altered blood flow in the brain (measured by magnetic resonance imaging (MRI)) and blood vessel function (measured by ultrasound).\n\nParticipants attended 3 visits over the course of the 4-month study. At the initial visit, participants completed a short questionnaire about their past medical history and medication history. At the baseline visit, participants were randomized in a 1:1 ratio to receive atorvastatin 40 mg nightly vs. matching placebo. At baseline and follow-up visits, participants provided an update on medical problems and medications, reviewed any potential side effects, and had fasting blood tests collected for safety monitoring, including liver and muscle enzyme monitoring. In addition, all participants had MRI and ultrasound measures collected.",
    "phase": [
        "PHASE2"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "PREVENTION",
    "results": null,
    "target_category": "N/A",
    "drug": [
        "Atorvastatin (Lipitor) \u2014 small-molecule HMG\u2011CoA reductase inhibitor (statin)"
    ],
    "placebo": [
        "Placebo (matching; used in the referenced randomized pilot trial)"
    ],
    "explanation_target": [
        "Reason: The intervention is atorvastatin, a small\u2011molecule statin whose primary pharmacologic action is competitive inhibition of HMG\u2011CoA reductase (lowers LDL cholesterol and exerts vascular/pleiotropic effects). The trial description tests whether atorvastatin improves cerebral perfusion, brain activity patterns, and endothelial (blood vessel) function in asymptomatic, middle\u2011aged adults at risk for AD \u2014 i.e., it targets vascular mechanisms thought to affect AD risk rather than canonical AD pathology (amyloid or tau) or direct symptomatic cognitive enhancement. \ue200cite\ue202turn1search2\ue202turn1search4\ue201",
        "Act: Key extracted details \u2014 drug: atorvastatin (oral statin); intervention aim: improve cerebral blood flow, cerebral perfusion, brain activity patterns, and endothelial function in asymptomatic adult children of persons with AD; study design (in the cited work): randomized, placebo\u2011controlled pilot trial showing atorvastatin increased regional cerebral blood flow in memory\u2011related areas after 4 months. These specifics support that the drug is a small\u2011molecule cardiovascular/vascular modifier rather than an anti\u2011amyloid or anti\u2011tau biologic or a classical cognitive enhancer. \ue200cite\ue202turn0search2\ue202turn0search0\ue201",
        "Reflect: Categorization rationale \u2014 the provided category definitions specify that \"disease\u2011targeted biologic\" refers to biologics (e.g., mAbs, vaccines) targeting AD pathology, and \"disease\u2011targeted small molecule\" was defined as small molecules targeting Alzheimer\u2019s pathology (amyloid/tau). Atorvastatin is a small molecule but its mechanism and the trial endpoints focus on vascular/vascular\u2011risk modification (cholesterol lowering, endothelial/flow effects), not direct targeting of amyloid or tau. It is also not primarily a symptomatic cognitive enhancer nor an agent aimed at neuropsychiatric symptoms. Therefore, the trial does not cleanly fit any of the four given categories and is best classified as 'N/A'. Supporting evidence: the pilot randomized study reported increased regional CBF with atorvastatin in at\u2011risk adults, and broader literature and meta\u2011analyses examine statins' possible association with reduced dementia risk but emphasize vascular/pleiotropic mechanisms and mixed evidence for direct AD disease\u2011modifying effects. \ue200cite\ue202turn0search2\ue202turn0search5\ue202turn1search6\ue201",
        "Web search results / sources used: (1) Pilot randomized study reporting atorvastatin increased regional cerebral blood flow in asymptomatic middle\u2011aged adults at risk for AD \u2014 Effects of Atorvastatin on Cerebral Blood Flow in Middle\u2011Aged Adults at Risk for Alzheimer\u2019s Disease: A Pilot Study (PMC/PubMed). \ue200cite\ue202turn0search2\ue202turn0search0\ue201 (2) Atorvastatin (Lipitor) prescribing information / mechanism summary (package insert / clinical pharmacology) describing HMG\u2011CoA reductase inhibition and vascular/pleiotropic effects. \ue200cite\ue202turn1search2\ue201 (3) Systematic reviews/meta\u2011analyses and bibliometric reviews examining statin use and dementia/AD risk (mixed evidence; possible protective associations in some observational studies). \ue200cite\ue202turn0search5\ue202turn0search1\ue201 (4) Safety and clinical profile literature for atorvastatin. \ue200cite\ue202turn0search3\ue201 (5) Reviews describing pleiotropic vascular effects of statins (endothelial function, anti\u2011inflammatory effects) relevant to the trial rationale. \ue200cite\ue202turn1search6\ue201"
    ],
    "agent_type": "N/A",
    "explanation_agent": []
}